The Weekly Litigation News Digest is now live. Subscribe now

Patent Oppositions in medicinal compounds for specific treatments industry

Explore the competitive field of medicinal compounds for specific treatments where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in medicinal compounds for specific treatments technology and learn how to protect your intellectual property.

Get Patent Opposition Report for medicinal compounds for specific treatments

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Nov 13, 2025
CompanyTotal Oppositions
NOVARTIS300
BOEHRINGER INGELHEIM119
AMGEN86
NOVO NORDISK77
PFIZER77
NUTRICIA62
NESTLE62
JANSSEN PHARMACEUTICA58
NESTEC54
BRISTOL MYERS SQUIBB48

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the medicinal compounds for specific treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the medicinal compounds for specific treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name
Use Of Isoxazoline Compounds For Treating DemodicosisINTERVETOct 28, 2025CEVA SANTE ANIMALE
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEOct 24, 2025CAMULON
Method And Compositions For Cellular ImmunotherapyFRED HUTCHINSON CANCER RESEARCH CENTEROct 8, 2025BOULT WADE TENNANT
Use Of Isoxazoline Compounds For Treating DemodicosisINTERVETOct 3, 2025VIRBAC
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEOct 1, 2025ELKINGTON AND FIFE
Combination Therapy For Inhalation AdministrationCHEMO RESEARCHOct 1, 2025HIGHTONE MANAGEMENT
ImmunoconjugatesTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYSep 30, 2025STRAWMAN
Combination DrugCHUGAI SEIYAKU KABUSHIKI KAISHASep 24, 2025BOTTI & FERRARI
Perinatal Administration Of Short-Chain Fructooligosaccharides In Order To Prevent Metabolic Disorders Linked To An Unbalanced Diet At Adult AgeINSTITUT NATIONAL DE RECHERCHE POUR LAGRICULTURESep 24, 2025SUDZUCKER
Nutritional CompositionNUTRICIASep 23, 2025NESTLE

To stay ahead in the competitive medicinal compounds for specific treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the medicinal compounds for specific treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA20
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS18
Oct 11, 2023New UseNOVARTIS17
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS15
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12